<DOC>
	<DOCNO>NCT02446769</DOCNO>
	<brief_summary>This multicenter , randomize , parallel-group , open label study efficacy AVAPS-AE prevent re-hospitalization hospitalize patient comorbid COPD .</brief_summary>
	<brief_title>A Pilot Study Assess Effects Novel Application Averaged Volume Assured Pressure Support Ventilation ( AVAPS-AE ) Therapy Re-hospitalization Patients With Sleep-Disordered Breathing With Co-morbid COPD</brief_title>
	<detailed_description>This multicenter , randomize , parallel-group , open label study efficacy AVAPS-AE prevent re-hospitalization hospitalize patient comorbid COPD . Hospitalized patient comorbid COPD high risk readmission recruit . Specifically patient comorbid COPD discharge ( ) admission diagnosis COPD ( GOLD stage II great ) ; AND ( b ) either prior non-elective hospitalization ( one past 12 month ) OR active smoker . Such participant undergo questionnaire-based screen sleep-disordered breathing ( STOP-BANG questionnaire ) high risk SDB ( &gt; 3 point ) undergo overnight portable sleep study screen prior hospital discharge ( AHI &gt; 10 per hour ; &gt; 3 % oxygen desaturation hypopnea ) . After randomization prior discharge , participant either initiated AVAPS-AE therapy ( intervention arm ) 60 day refer sleep center diagnostic test therapy initiation ( standard care arm ) . Participants complete quality life questionnaire ( Functional outcomes sleep questionnaire [ FOSQ ] ) baseline ( in-person ) , 30 60 day ( mail ) post discharge . Information regard hospital admission , diagnostic test , medication change , procedure collect participant . Discharge summary re-hospitalizations office ER visit , well diagnostics test therapy receive collected measuring healthcare cost . Participants option enroll registry 3 year follow-up also query yearly basis regard hospitalization , cardiovascular event , assessment vital statistic National Death Index registry . The study conclude randomize participant follow minimum 60 day .</detailed_description>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>1 . Hospitalized patient high risk readmission least 18 year age . 2 . Specifically patient ( ) admission diagnosis COPD AND ( b ) either prior nonelective hospitalization ( One past 12 month ) OR active smoker ready discharge AND ( c ) also find sleepdisordered breathing ( AHI â‰¥ 10 per hour ; &gt; 3 % oxygen desaturation hypopnea ) overnight portable respiratory study prior hospital discharge . 3 . Bedside spirometry reveal evidence obstructive lung disease ( postbronchodilator ; GOLD stage II great ( FEV1 &lt; 70 % predict post BD ) . 4 . No previous home PAP NIV use within past year 1 . Central sleep apnea ( Central apnea index &gt; 5 per hour ; and/or &gt; 50 % central apneas &amp; hypopnea ) 2 . Clinically unstable , i.e. , Acute Respiratory Failure , hypotensive shock , uncontrolled cardiac ischemia arrhythmia , require life support ventilation otherwise determine investigator 3 . Participants Stage III &amp; IV Chronic Heart Failure define New York Heart Association ( NYHA ) Classification 4 . Known expected contraindication use noninvasive ventilation per assessment investigator . 5 . Lack medical insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>